Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001714899-23-000017)

Filing Details

Accession Number:: 0001714899-23-000017
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-01-10 16:51:18
Reporting Period:: 2023-01-09

Accepted Time:: 2023-01-10 16:51:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	Biological Products, (No Disgnostic Substances) (2836)	463872213

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1724605	Carole Ho	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-01-09	1,459	$28.48	177,454	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	25,000	Indirect	See footnote
Common Stock	131,467	Direct

Footnotes

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
Includes 131,057 RSUs.